Key Points
- Director Badreddin Edris sold 115,471 shares on Jan. 21 at an average of $29.44 for about $3.40 million, cutting his stake by 85.35% to 19,820 shares.
- EWTX opened at $28.61 (12‑month range $10.60–$30.48) with a market cap of $3.03 billion, and analysts hold a consensus "Moderate Buy" with an average target of $36.67.
- Edgewise is a clinical‑stage biopharma focused on rare diseases; its lead program, EWTX‑101, is an oral TRPC5 inhibitor aimed at FSGS and other proteinuric kidney disorders.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) Director Badreddin Edris sold 115,471 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the sale, the director owned 19,820 shares of the company's stock, valued at approximately $583,500.80. The trade was a 85.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Edgewise Therapeutics Stock Down 3.9%
EWTX stock opened at $28.61 on Friday. Edgewise Therapeutics, Inc. has a twelve month low of $10.60 and a twelve month high of $30.48. The company has a market cap of $3.03 billion, a PE ratio of -18.11 and a beta of 0.27. The business's 50-day simple moving average is $24.62 and its 200 day simple moving average is $18.42.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. On average, equities research analysts anticipate that Edgewise Therapeutics, Inc. will post -1.45 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on EWTX. JPMorgan Chase & Co. lifted their price target on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the stock an "overweight" rating in a research note on Friday, November 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edgewise Therapeutics in a research report on Wednesday. Wall Street Zen raised shares of Edgewise Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday. Royal Bank Of Canada raised their price target on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an "outperform" rating in a research note on Friday, November 7th. Finally, Wedbush decreased their price objective on Edgewise Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $36.67.
View Our Latest Report on EWTX
Institutional Investors Weigh In On Edgewise Therapeutics
Large investors have recently made changes to their positions in the company. Jones Financial Companies Lllp acquired a new stake in shares of Edgewise Therapeutics during the 1st quarter worth about $47,000. Bessemer Group Inc. grew its stake in Edgewise Therapeutics by 1,170.3% during the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company's stock worth $38,000 after buying an additional 2,165 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Edgewise Therapeutics during the second quarter worth approximately $45,000. Strs Ohio bought a new position in shares of Edgewise Therapeutics in the first quarter valued at approximately $84,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Edgewise Therapeutics by 28.2% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,062 shares of the company's stock valued at $53,000 after acquiring an additional 894 shares during the last quarter.
Edgewise Therapeutics Company Profile
(
Get Free Report)
Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.
At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
